Sino Biological US, Inc. has announced the launch of ProPure™, a new line of ultra-pure, endotoxin-free recombinant proteins, produced at its Center for Bioprocessing (C4B) facility in Houston, Texas. This innovation is set to meet the high demands of immunology research, vaccine development, and therapeutic protein manufacturing, among other sensitive applications.
The ProPure™ proteins are manufactured using advanced purification technologies, ensuring endotoxin levels are below the limit of quantification. This achievement is significant for researchers and biomanufacturers who require the highest standards of quality and consistency for breakthroughs in basic and translational science.
Dr. Rob Burgess, Chief Business Officer at Sino Biological US, emphasized the company's commitment to scientific excellence and product safety. The introduction of ProPure™ reflects Sino Biological's investment in bioprocessing innovation and its support for the global life sciences community.
In addition to its standard offerings, the C4B facility provides customized protein development services, catering to unique research and production needs. This flexibility further positions Sino Biological as a key player in the life sciences sector.
The launch of ProPure™ is a testament to Sino Biological's dedication to advancing scientific research and therapeutic developments, offering researchers and manufacturers reliable, high-quality proteins for their critical work.
